Geno Germano - Pfizer President
PFE Stock | EUR 25.60 0.15 0.59% |
President
Mr. Geno J. Germano is Group President Global Innovative Pharma Business of Pfizer Inc. since January 2014. He was President and General Manager Pfizer Specialty Care and Oncology from December 2010 until December 2013. President and General Manager Specialty Care from October 2009 until December 2010. President U.S. Pharmaceuticals and Womens Health Care Unit Wyeth Pharmaceuticals from 2008 through October 2009. President and General Manager U.S. Pharmaceutical Business Unit Wyeth Pharmaceuticals from 2007 through 2008. Member of the Board of Trustees for Albany College of Pharmacy and Health Sciences and Member of the Board of Directors of BIO Biotechnology Industry Organization. Director of Zoetis Inc. from July 2012 until June 2013. since 2014.
Age | 53 |
Tenure | 10 years |
Phone | 212 733 2323 |
Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1287 % which means that it generated a profit of $0.1287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3622 %, meaning that it generated $0.3622 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
Barton Peterson | Eli Lilly And | 57 | |
Rob Dorran | Superior Plus Corp | N/A | |
Maria Crowe | Eli Lilly And | 55 | |
Jeffrey Simmons | Eli Lilly And | 48 | |
Michael Farrell | Superior Plus Corp | N/A | |
Michael Harrington | Eli Lilly And | 53 | |
Gavin Harvey | NorAm Drilling AS | 59 | |
Jimmy Castro | NorAm Drilling AS | 50 | |
Alfonso Zulueta | Eli Lilly And | 53 | |
Andrew Peyton | Superior Plus Corp | 55 | |
David Eldersveld | NorAm Drilling AS | N/A | |
Melissa Barnes | Eli Lilly And | 47 | |
Leigh Pusey | Eli Lilly And | 60 | |
Lawrence Wert | NorAm Drilling AS | 61 | |
Fionnuala Walsh | Eli Lilly And | 56 | |
Gregory McCamus | Superior Plus Corp | N/A | |
Joshua Smiley | Eli Lilly And | 47 | |
Jay Bachman | Superior Plus Corp | N/A | |
David Ricks | Eli Lilly And | 55 | |
Shawn Vammen | Superior Plus Corp | N/A | |
Enrique Conterno | Eli Lilly And | 49 |
Management Performance
Return On Equity | 0.36 | |||
Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President - Global Established Pharma Business | ||
Jennifer Damico, Controller VP | ||
Frank DAmelio, CFO, Executive Vice President - Business Operations | ||
Douglas Lankler, Executive Vice President General Counsel | ||
Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
Helen Hobbs, Independent Director | ||
Shantanu Narayen, Director | ||
James Smith, Director | ||
Christopher CFA, VP Officer | ||
Dennis Ausiello, Independent Director | ||
Mikael Dolsten, President - Worldwide Research and Development | ||
Frances Fergusson, Independent Director | ||
Stephen Sanger, Independent Director | ||
Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
Wyllie Cornwell, Independent Director | ||
Suzanne Johnson, Independent Director | ||
David Denton, Chief VP | ||
Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
DVM DVM, Chairman CEO | ||
Geno Germano, Group President - Global Innovative Pharma Business | ||
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations | ||
Sally Susman, Executive Vice President - Corporate Affairs | ||
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply | ||
Freda LewisHall, Executive Vice President Chief Medical Officer | ||
Rady Johnson, Executive Vice President Chief Compliance and Risk Officer | ||
Mikael MD, Dev Research | ||
Dan Littman, Director | ||
Ian Read, Chairman of the Board, CEO | ||
James Kilts, Independent Director | ||
Don Cornwell, Independent Director | ||
Charles Hill, Executive Vice President - Worldwide Human Resources | ||
Joseph Echevarria, Director | ||
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply | ||
Angela Hwang, Group President - Pfizer Essential Health | ||
Scott Gottlieb, Director | ||
Ronald Blaylock, Independent Director | ||
Kathrin Jansen, Senior Vice President - Vaccine Research & Development | ||
Michael Goettler, Group President - Pfizer Upjohn |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.36 | |||
Return On Asset | 0.13 | |||
Profit Margin | 0.31 % | |||
Operating Margin | 0.39 % | |||
Current Valuation | 276.06 B | |||
Shares Outstanding | 5.62 B | |||
Shares Owned By Insiders | 0.04 % | |||
Shares Owned By Institutions | 71.00 % | |||
Price To Earning | 16.17 X | |||
Price To Book | 3.13 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |